Evidence map›Paper›PMID 34983117›Full record

ReviewInvestigative and clinical urology2022

Immunotherapy for prostate cancer: Requirements for a successful regime transfer.

Seung-Hwan Jeong, Cheol Kwak

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Investigative and clinical urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. ZIF-8 nanoplatform coordinating ZnInternational journal of pharmaceutics: X · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Seung-Hwan JeongDepartment of Urology, Seoul National University Hospital, Seoul, Korea.ORCID 0000-0002-8076-3643
Cheol KwakDepartment of Urology, Seoul National University Hospital, Seoul, Korea.ORCID 0000-0002-1987-2111

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the revolutionary progress in cancer treatment using immune checkpoint inhibitors (ICIs), remarkable responses in prostate cancer treatment have not yet been achieved. The disappointing previous results of ICIs have required further studies towards combined treatment targeting other pathways and restricted the eligibility criteria for patients with high mutation burdens, especially those with mismatch repair deficiency. Cancer immunotherapies activate adaptive immune systems, rather than directly attack tumor cells with their own cytotoxicity. Therefore, refractoriness to ICIs can not only be derived from the intractable nature of tumor cells

Indexed as

ImmunotherapyHumansMaleProstatic NeoplasmsTumor MicroenvironmentImmunotherapyProstatic neoplasmsTumor microenvironment

Identifiers

PMID34983117
PMCPMC8756154

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.